Insulin Efsitora Alfa + Insulin Degludec
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes
Conditions
Diabetes, Type 2 Diabetes
Trial Timeline
Jun 3, 2022 โ Apr 10, 2024
NCT ID
NCT05362058About Insulin Efsitora Alfa + Insulin Degludec
Insulin Efsitora Alfa + Insulin Degludec is a phase 3 stage product being developed by Eli Lilly for Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05362058. Target conditions include Diabetes, Type 2 Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05463744 | Phase 3 | Completed |
| NCT05362058 | Phase 3 | Completed |
| NCT05275400 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes